BioAge Labs stock rallied Thursday on the company's upsized IPO — reflecting enthusiasm for its approach to obesity ...

Shares of BioAge Labs (BIOA), a biopharmaceutical company focused on obesity drugs, opened 25% above its initial public ...

The arrival of GLP-1 analog drugs (such as Wegovy) marked a huge shift in the weight-loss drug market. These drugs have been ...

Pfizer's decision late on Wednesday to withdraw its sickle cell disease treatment due to the risk of death could help speed ...

Viking Therapeutics (VKTX) leads the race to win FDA Rx-to-OTC switch for an oral weight loss drug belonging to GLP-1 class ...

Terns Pharma is in the process of developing TERN-601 for the treatment of patients with obesity. See why I rate TERN stock ...

Sometimes diet and exercise are not enough to help the 100 million Americans with obesity lose weight and prevent health ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

An experimental weight loss pill developed by biotechnology company Terns Pharmaceuticals helped some people with obesity lose more than 5% of their body weight in a small Phase 1 trial, supporting ...

Novo Nordisk said on Wednesday that its highly anticipated experimental weight-loss pill amycretin was safe and tolerable for patients in an early ... data from an early study on a subcutaneous ...

The net prices of Ozempic and Wegovy, or the amount that Novo Nordisk is actually paid for the drugs, have dropped substantially since their launch and are expected to fall even further, said Lars ...

In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.